Axovant gene therapies ltd. (AXON)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent

-65,046

-85,242

-105,277

-129,065

-145,338

-168,944

-204,195

-221,573

-249,087

-238,996

-212,162

-180,951

-157,789

-173,333

-146,247

-133,145

-113,759

-61,166

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Loss on disposal of fixed assets

-155

-164

-173

-148

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign currency translation adjustment

466

81

746

-785

128

-444

-656

252

-792

-128

-29

-378

0

0

0

-

-

-

-

-

-

Amortization of operating lease right-of-use assets

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation expense

8,893

11,139

12,705

16,429

3,173

9,254

22,137

31,878

50,120

47,812

40,409

36,370

36,257

66,982

64,770

72,386

72,254

33,198

0

0

0

Depreciation and non-cash amortization

1,502

1,537

1,842

2,450

3,093

3,680

3,782

3,083

2,327

1,277

573

249

41

22

24

14

8

14

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-1,400

284

-1,895

3,685

2,788

-492

-179

-4,283

-2,139

482

4,327

1,592

415

2,073

3,270

4,860

3,816

2,031

0

0

0

Deferred tax assets

-

-

-

-

-

-

-

-2,709

-323

-40

-323

2,386

0

0

0

-

-

0

0

-

-

Income tax receivable

408

541

300

-25

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

-2,817

-3,692

-3,151

973

3,449

4,324

3,784

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Accounts payable

-671

-250

1,465

-2,251

-14

-1,043

-7,116

-4,602

-8,219

-6,650

5,704

7,929

5,695

8,813

2,212

219

3,270

411

0

0

0

Due to Roivant Sciences Ltd. and certain of its wholly owned subsidiaries

-

0

-2,252

-

-

-1,333

-2,225

-1,871

-3,587

1,536

2,248

1,105

3,603

247

437

-311

-52

1,821

0

0

0

Accrued expenses

-2,543

-2,854

2,647

-11,243

-12,024

-9,479

-12,908

-2,934

9,538

17,367

26,169

26,477

20,000

14,490

10,633

8,391

5,931

2,477

0

0

0

Operating lease liabilities

-

-

0

-

-

-

0

-

-2,164

-2,450

-740

0

119

196

107

185

98

284

0

0

0

Net cash used in operating activities

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-80,211

-67,378

-53,347

-30,814

-15,380

0

0

0

Cash flows from investing activities:
Purchase of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Purchases of property and equipment

378

358

280

202

112

659

2,113

4,284

4,246

3,712

2,248

105

140

93

115

94

68

46

0

0

0

Net cash used in investing activities

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,345

-5,367

-5,346

-4,824

-5,046

0

0

0

Cash flows from financing activities:
Payments on long-term debt

34,490

19,962

14,754

9,707

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

336,893

336,893

336,893

0

0

0

Initial public offering costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,351

2,376

2,376

0

0

0

Capital contribution received from Roivant Sciences, Inc.

904

1,548

1,922

1,894

0

0

0

-

-

-

-

-

-

-

-

751

750

5,751

0

0

0

Repayment of amounts due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

627

627

627

0

0

0

Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

278

996

996

0

0

0

Payment of contingent liability

-

-

-

-

-

-

-

-

-

-

-

5,000

5,000

5,000

5,000

0

0

0

0

-

-

Cash proceeds from stock option exercises

128

303

330

335

293

189

820

1,557

1,583

1,512

783

36

0

0

0

-

-

-

-

-

-

Cash proceeds from issuance of common shares, net of costs

-

-

-

-

-

-

-

134,515

134,515

134,515

134,628

0

0

0

0

-

-

-

-

-

-

Net cash (used in) provided by financing activities

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,991

-5,667

334,944

335,636

340,637

0

0

0

Net change in cash and cash equivalents

-

0

0

-

-

0

0

-

-12,154

5,709

45,201

-63,678

-99,593

-90,547

-78,412

276,251

299,998

320,211

0

0

0

Unpaid initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

Non-cash operating activities:
Operating lease right-of-use assets recognized upon the adoption of ASC 842, Leases, on April 1, 2019

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities recognized upon and since the adoption of ASC 842, Leases, on April 1, 2019

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amounts reclassified from other non-current assets to operating lease right-of-use assets upon the adoption of ASC 842, Leases, on April 1, 2019

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,278

1,279

804

203

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-